Neurocrine Biosciences Inc

Neurocrine insider trading: a director’s buy at $47.89 and sell at $157.65 shows long‑term confidence and market stability—why investors should watch upcoming trials.

Neurocrine insider sells 3,810 shares via 10b5‑1 plan, signaling strategic divestment while market remains bullish and investor confidence stays high.

Insider trading at Neurocrine Biosciences shows steady confidence: executives buy/sell for liquidity but maintain long‑term stakes, keeping volatility low and focusing on future neuro‑psychiatric breakthroughs.

Insider buying surge at Neurocrine shows executive confidence ahead of Phase 2 data; could lift the stock toward its recent high.

Neurocrine CFO’s fresh buy signals insider confidence amid rising stock, highlighting upcoming Phase‑2 data that could boost a biotech rally.

Neurocrine insider Bénévich’s 12,830‑share option exercise signals strong confidence in its pipeline and may boost investor sentiment ahead of earnings.

Neurocrine insider buying: CCO Eric Ben Evi­ch purchases 12,830 shares at $35.99, signaling confidence amid a 52‑week low and potential upside for investors.